LBPH vs. AVTE, BCYC, YMAB, PHAR, ORIC, SLN, SIGA, ZYME, PRTC, and PRAX
Should you be buying Longboard Pharmaceuticals stock or one of its competitors? The main competitors of Longboard Pharmaceuticals include Aerovate Therapeutics (AVTE), Bicycle Therapeutics (BCYC), Y-mAbs Therapeutics (YMAB), Pharming Group (PHAR), ORIC Pharmaceuticals (ORIC), Silence Therapeutics (SLN), SIGA Technologies (SIGA), Zymeworks (ZYME), PureTech Health (PRTC), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical preparations" industry.
Aerovate Therapeutics (NASDAQ:AVTE) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, community ranking, risk and earnings.
Aerovate Therapeutics presently has a consensus target price of $49.33, indicating a potential upside of 135.59%. Longboard Pharmaceuticals has a consensus target price of $39.50, indicating a potential upside of 103.08%. Given Longboard Pharmaceuticals' higher possible upside, equities analysts clearly believe Aerovate Therapeutics is more favorable than Longboard Pharmaceuticals.
Aerovate Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Longboard Pharmaceuticals has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.
Longboard Pharmaceuticals' return on equity of -61.62% beat Aerovate Therapeutics' return on equity.
63.3% of Longboard Pharmaceuticals shares are held by institutional investors. 19.3% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 4.6% of Longboard Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Longboard Pharmaceuticals received 24 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. Likewise, 71.43% of users gave Longboard Pharmaceuticals an outperform vote while only 64.00% of users gave Aerovate Therapeutics an outperform vote.
Longboard Pharmaceuticals is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aerovate Therapeutics had 9 more articles in the media than Longboard Pharmaceuticals. MarketBeat recorded 10 mentions for Aerovate Therapeutics and 1 mentions for Longboard Pharmaceuticals. Aerovate Therapeutics' average media sentiment score of 0.59 beat Longboard Pharmaceuticals' score of 0.36 indicating that Longboard Pharmaceuticals is being referred to more favorably in the news media.
Summary
Longboard Pharmaceuticals beats Aerovate Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Longboard Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LBPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longboard Pharmaceuticals Competitors List
Related Companies and Tools
